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ABSTRACT
Periostin is a 90-kDa member of the fasciclin-containing family; it functions as part of matricellular proteins, and
its production by airway epithelial cells is induced by IL-4 and IL-13. Periostin is secreted by fibroblasts and
upregulated in the airway epithelia of patients with bronchial asthma; it is considered to contribute to remodel-
ing under this pathological condition. However, despite many studies in diverse research areas, our overall un-
derstanding of this intriguing molecule is still inadequate. Here, we integrate the available evidence on periostin
expression and its roles in otolaryngological diseases, including allergic rhinitis, chronic rhinosinusitis with na-
sal polyps, aspirin-induced asthma, organized hematoma, eosinophilic otitis media, and IgG4-related disease.
Periostin might be involved as an important structural mediator in pathological processes such as insult and in-
jury, Th2-driven inflammation, extracellular matrix restructuring, fibrosclerosis, tumor angiogenesis, and tissue
remodeling.
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INTRODUCTION
Periostin is a recently characterized matricellular pro-
tein originally isolated from an osteoblast cell line; its
production is induced by IL-4 and IL-13 in airway epi-
thelial cells.1 Periostin is also a regulator of fibrosis
and collagen deposition. It is widely observed in vari-
ous chronic inflammatory diseases, and it plays an
important role in bronchial asthma, atopic dermatitis,
myocardial repair and remodeling following myocar-
dial infarction, eosinophilic esophagitis, proliferative
diabetic retinopathy, bone marrow fibrosis, and fi-
brotic remodeling.2-9 However, evidence for a rela-
tionship between periostin and various otolaryn-
gological disorders is still scarce. Here, we present
the expressions and roles of periostin in local tissues
from patients with otolaryngological diseases, includ-
ing allergic rhinitis (AR), chronic rhinosinusitis with
nasal polyps (CRSwNP), aspirin-induced asthma
(AIA), organized hematoma, eosinophilic otitis me-
dia, and IgG4-related disease.
AR AND CHRONIC RHINOSINUSITIS (CRS)
AR is a Th2-mediated inflammatory disease charac-
terized by mucosal eosinophilia, airway hyperrespon-
siveness, and mucus overproduction.10,11 With subse-
quent progression of AR, the airways undergo struc-
tural and phenotypic changes resulting in airway re-
modeling, including damage to epithelial cells, goblet
cell metaplasia, subepithelial fibrosis, and smooth
muscle hyperplasia and hypertrophy.12,13 Expression
of periostin has been observed in bronchial epithelial
tissue, and periostin might play an important role in
tissue remodeling in bronchial asthma.14 Periostin is
observed in normal nasal tissues, but it is expressed
more strongly in the basement membranes of pa-
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Fig.　1　Immunohistochemical staining of periostin in nasal mucosa. (A) Weak expression of periostin was detected in 
the basement membrane of normal nasal mucosa (original magnifi cation ×100). (B) Moderate expression of periostin 
was observed in the nasal mucosa in allergic rhinitis (AR) (original magnifi cation ×100). (C) Strong expression was ob-
served in the nasal mucosa in chronic rhinosinusitis with nasal polyps (CRSwNP) (original magnifi cation ×100). (D) High-
power-fi eld image of periostin-positive infi ltrating cells in the nasal mucosa of a patient with CRSwNP (high-power fi eld, 
×400). (E) Strong expression was also detected in nasal polyp tissue in aspirin-induced asthma (AIA) (original magnifi ca-
tion ×100). (F) Determination of periostin volume per surface area of basal lamina. Periostin staining was signifi cantly 
more intense in AR, CRSwNP, and AIA than in the control. Results are shown as means ± SD (n = 10 in each group). 
*P < 0.05 vs. control; # P < 0.05 vs. allergic rhinitis. (Data obtained from reference 15.)
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tients with AR than in controls (Fig. 1).15 The patients
with AR from whom the sections in Figure 1 were
taken showed a very poor response to various medi-
cal treatments and finally underwent inferior tur-
binectomy and posterior nasal neurectomy. These
findings support the concept that periostin is involved
in Th2-driven inflammation and tissue remodeling in
AR.15
CRSwNP is one of the most frequently encoun-
tered chronic nasal diseases, and the growth of pol-
yps leads to obstruction of the sinonasal passages.
Surgery may be mandatory to remove the polyps and
restore sinus ventilation in advanced cases.13,14
Aspirin-induced asthma (AIA) is a subset of
CRSwNP. This is characterized by the presence of na-
sal polyps, asthma, and aspirin intolerance.13,14 In in-
dividuals with AIA, intake of nonsteroidal anti-
inflammatory agents, including aspirin, leads to im-
mediate and severe bronchospasm, resulting in the
need for treatment in the emergency room.14 It has
been hypothesized that a common stimulus causes
inflammation of both the sinonasal and the bron-
chopulmonary mucosa.13,14 Histologically, prolifera-
tion and thickening of the mucosal epithelium, with
focal squamous metaplasia, glandular hyperplasia,
subepithelial fibrosis, and stromal edema with numer-
ous blood vessels, are observed in nasal polyp tis-
sues.13,15 One of the most important characteristics of
CRS is the prolonged and exaggerated inflammatory
reaction in the paranasal mucous membranes.13-15
Strong periostin production in the sinonasal tissues
has been observed in the basement membranes, na-
sal polyps, and infiltrating cells of patients with
CRSwNP and AIA (Fig. 1).15 Moreover, the levels of
periostin production were increased in CRSwNP
model mouse.16 The concentrations of periostin in
the sera and nasal lavage fluids were measured by en-
zyme linked immunoassay.2 The specificities and sen-
sitivities of periostin levels in the sera and nasal lav-
age fluids were evaluated by using ROC curve analy-
sis to distinguish patients with CRSwNP from control
subjects or patients with AR. From the ROC curve,
the respective optimal cutoff points (red lines) were
found at 95 and 0.8 ngmL with the highest Youden’s
index, which gave good specificity (98.5% and 100%,
respectively) and good sensitivity (68.2% and 100% re-
spectively) (Fig. 2). We have also found that periostin
concentrations in the sera and nasal lavage fluids are
Periostin in Otolaryngologic Diseases
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Fig.　2　Concentrations of periostin in the sera of patients with chronic rhinosi-
nusitis with nasal polyps (CRSwNP) or controls or in the nasal lavage fl uids of 
patients with CRSwNP or allergic rhinitis (AR). The serum concentration of peri-
ostin was signifi cantly greater in CRSwNP (116.6 ± 20.7) than in the control 
group (39.1 ± 11.7) (P < 0.01). The concentration of periostin in nasal lavage fl u-
ids was signifi cantly greater in CRSwNP patients (2.3 ± 0.9) than in patients with 
AR (0.2 ± 0.1) (P < 0.01). Horizontal bars indicate median values. Results are 
means ± SD.
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Fig.　3　Association between serum periostin level and 
complicated allergic diseases. Patients with chronic rhinosi-
nusitis with nasal polyps (CRSwNP) were allocated to three 
categories. The serum concentration of periostin was signifi -
cantly greater in patients with CRSwNP complicated by 
bronchial asthma alone (148.7 ± 93.7) or by both allergic 
rhinitis (AR) and bronchial asthma (123.2 ± 77.8) than in 
non-atopic patients (84.2 ± 23.7) (*P < 0.05). Horizontal 
bars indicate median values. Results are means ± SD.
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greater in patients with CRS than in healthy control
subjects or patients with AR in limited cases (Fig. 2).
Taken together, these findings demonstrate that
measurement of periostin in the sera and nasal lavage
fluids would be useful for distinguishing patients with
CRS from patients with AR or healthy controls. The
underlying mechanism of polyp formation in
CRSwNP is still mystery. However, these findings
strongly support the suggestion that periostin is pro-
duced locally in the sinonasal tissues and contributes
to polyp formation. Interestingly, we have found that
serum periostin concentrations are elevated in pa-
tients with CRS complicated by bronchial asthma
(Fig. 3). Patients with bronchial asthma have in-
creased serum periostin levels.2 Periostin regulates
goblet cell metaplasia and mucus production in air-
way inflammation, including in bronchial asthma.17
These findings indicate that periostin plays an impor-
tant role in the pathogenesis of CRSwNP and bron-
chial asthma. We have found that the number of
eosinophils and the concentration of eosinophil cat-
ionic protein are significantly higher in patients with
high serum periostin levels than in patients with low
serum periostin levels in more larger series study
(Fig. 4). Periostin could activate eosinophils and sus-
tain eosinophil-mediated inflammation and fibrosis in
Ohta N et al.
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Fig.　4　Association between serum periostin level and percentage of eosinophils in 
peripheral blood or level of eosinophil cationic protein (ECP). Patients with CRSwNP 
were categorized into two periostin level groups. From the ROC curve, the optimum 
cut-off point of periostin was 95 ng/mL. The number of eosinophils was signifi cantly 
greater in patients in the High periostin group (>95 ng/mL, 6.5 ± 4.7) than in patients 
in the Low periostin group (<95 ng/mL, 3.3 ± 2.1) (**P < 0.01). The serum concen-
tration of eosinophil cationic protein (ECP) was also signifi cantly higher in patients 
in the High periostin group (86.1 ± 54.3) than in patients in the low periostin group 
(52.7 ± 16.3) (*P < 0.05). Horizontal bars indicate median values. Results are 
shown as means ± SD.
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the asthmatic airway.15
Taken together, these findings allow us to specu-
late that periostin plays important roles in fibrosis of
the nasal epithelial tissues and mucus hyperproduc-
tion in CRSwNP and AIA by orchestrating the activa-
tion and chemotaxis of eosinophils. Periostin may
therefore be a brand new therapeutic target for pre-
venting fibrosis in these sinonasal diseases in future.
ORGANIZED HEMATOMA
The clinical features of organized hematoma, such as
the presence of a mass expanding from the maxillary
sinus, with bone destruction, resemble those of max-
illary carcinoma.18,19 A heterogeneous signal inten-
sity on magnetic resonance imaging (MRI) is com-
monly observed in organized hematoma.20 The patho-
logical findings of organized hematoma include hem-
orrhage, fibrin exudation, fibrosis, hyalinization, and
neovascularization in the subepithelium.18 The ap-
pearance of these findings varies among different
parts of the mass.18 Expressions of CD31, CD34, and
periostin is observed in organized hematoma of the
maxillary sinus (Fig. 5).21 CD31 is a marker of endo-
thelial cells. CD31 immunostaining shows that the en-
dothelial cells keep their structural integrity and di-
lated pattern in limited areas.21 CD34 is a marker of
endothelial cell progenitors and neovascularization. It
is also moderately expressed around the necrotic tis-
sues in organized hematoma.21 Periostin is strongly
expressed around the neovascularized and fibrotic ar-
eas in this condition (Fig. 5).21 Periostin is a regulator
of fibrosis and collagen deposition and is also in-
volved in angiogenesis in tumors.20 The underlying
mechanism of organized hematoma is also still mys-
tery. However, the vicious circle theory has been sug-
gested to explain the disease etiology as follows: a
blood clot accumulates in a closed space as a result of
bleeding from various causes, including hemangioma
formation, facial injury, or inflammation. Necrosis, fi-
brosis, and hyalinization then occur in turn, and ne-
ovascularization develops as part of these normal
healing processes. These processes are mandatory
for tissue repair and wound healing under physiologi-
cal conditions. However, blood flow becomes slug-
gish in the area of new vessels, because the hema-
toma occurs within a closed space. As a result, the
newly formed vessels are damaged, and rebleeding
easily occurs due to breakdown of the new vessels.20
Taken together, these findings allow us to speculate
that periostin plays an important role in the vicious
Periostin in Otolaryngologic Diseases
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Fig.　5　Representative pathological fi ndings in organized hematoma. (A) Non-neoplastic tissue 
with hemorrhage, fi brin exudation, and hyalinization was observed (HE, original magnifi cation 
×100). (B) Strong staining for CD31-positive cells was observed in the organized hematoma, and 
dilated vessels were found (immunostaining, original magnifi cation ×100). (C) Moderate amounts 
of CD34-positive cells were also observed in the organized hematoma (immunostaining, original 
magnifi cation ×200). (D) Immunohistochemical staining for periostin in organized hematoma. Ex-
pression of periostin was observed diffusely in neovascularized and highly fi brotic areas (original 
magnifi cation ×100). (Data partially obtained from reference 21.)
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Fig.　6　Vicious circle of periostin-associated organized he-
matoma formation in sinonasal cavity. Necrosis, fi brosis, hy-
alinization, and subsequent neovascularization usually work 
well in normal wound healing. However, if newly generated 
vessels break down, rebleeding occurs easily and the heal-
ing process is interrupted. This vicious circle might be in-
volved in organized hematoma formation.
Schema of the growing organized hematoma 
Bleeding 
Necrosis 
Fibrosis Hyalinization 
Neovascularization 
Periostin
Vicious
Circle 
circle as an inducer of fibrosis and angiogenesis in or-
ganized hematoma formation (Fig. 6).21
EOSINOPHILIC OTITIS MEDIA
Eosinophilic otitis media (EOM) is a newly recog-
nized intractable middle ear disease that is character-
ized by the accumulation of eosinophils in middle ear
effusions and the middle ear mucosa.22,23 Unlike the
granulation due to conventional chronic otitis media,
the granulation tissue of EOM is generally resistant
to all therapies except for steroid treatment, and the
etiology of its formation is still mystery. To clarify the
mechanism underlying EOM, various mediators and
cytokines in middle ear effusions have been investi-
gated. Higher concentrations of IL-5, eotaxin, and IgE
have been detected in the middle ear effusions of
EOM patients than in controls.24 IL-5 is a chemokine
mediating eosinophil migration; it activates eosino-
phils and increases cell survival.24 However, the role
of periostin in EOM has not been reported recently.
We have found that periostin is strongly expressed in
Ohta N et al.
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Fig.　7　Representative cases of eosinophilic otitis media (EOM) in an elderly Japanese woman and a young Japanese 
man. (A) The swelling and perforation of the right tympanic membrane is observed in the granulation tissue of EOM pa-
tients with bronchial asthma. (B) The high grade of eosinophil infi ltration is observed in middle ear granulation tissue ob-
tained from EOM patient with bronchial asthma (HE, original magnifi cation ×200). (C) Periostin was expressed in the 
middle ear granulation tissues of EOM patients without bronchial asthma (immunohistochemical staining ×160). (D) 
Strong staining for periostin was observed in middle ear granulation tissues from EOM patients with bronchial asthma 
(×160). (E) IL-13-positive infi ltrating cells (black; arrowheads) were detected in middle ear granulation tissue obtained 
from an EOM patient with bronchial asthma (high-power fi eld ×400).
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the basement membranes and granulation tissues,
with variable grades of infiltration of eosinophils in
granulation tissues obtained from EOM patients with
or without bronchial asthma (Fig. 7).25 Stronger im-
munoreactivity for periostin has been observed in
EOM patients with bronchial asthma than in EOM
patients without bronchial asthma.25 In the animal
model of EOM, immunoreactivity to periostin is also
seen in the middle ear tissues.26 We have observed
IL-13 positive cells in granulation tissue obtained
from EOM patients with bronchial asthma (Fig. 7).
IL-13 is produced from Th2 cells and is a strong in-
ducer of periostin production in bronchial asthma.1,2
Collectively, our findings demonstrate that periostin
might contribute to Th2-driven inflammation and re-
modelling in EOM as well as AR and CRSwNP. Pa-
tients with EOM have a high risk of conductive hear-
ing loss in the early stage, but some patients develop
an increased bone-conduction threshold, leading to
deafness.22,23,25 The mechanism underlying sensory
hearing loss in EOM is still unclear, but not only the
middle ear but also the inner ear, including the coch-
lea, scala tympani of the organ of Corti, and capillar-
ies of the stria vascularis, is infiltrated with eosino-
phils to variable degrees in an animal model of
EOM.26 Taken together, these results suggest that
eosinophilic inflammation in the middle ear directly
influences inner ear function.26
IgG4-RELATED DISEASE
IgG4-related disease is a rapidly emerging entity. It
is characterized clinicopathologically by idiopathic
and symmetrical enlargement of the submandibular,
lacrimal, and parotid glands, marked serum IgG4
elevation, and infiltration of affected organs by plas-
mocytes bearing IgG4.27 In addition, IgG4-related
disease is associated with several potentially life-
threatening clinical conditions, namely autoimmune
pancreatitis, sclerosing cholangitis, retroperitoneal fi-
brosis, tubulointestinal nephritis, prostatitis, scleros-
ing cholecystitis, inflammatory pseudotumor of the
lung, liver, or inflammatory aortic aneurysm and or
hypophysis (Fig. 8).28,29 CT, MRI, and histopathologi-
cal information from a typical case are shown in Fig-
ure 9. The pathological findings in salivary glands af-
fected by IgG4-related disease are characterized by
lymphoplasmacytic infiltration, lymphoid follicle for-
mation, and variable degrees of fibrosclerosis. Fibro-
sclerosis is a chronic pathological consequence of the
inflammatory response and leads to distortion of tis-
Periostin in Otolaryngologic Diseases
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Fig.　8　Concepts of IgG4-related disease. IgG4-related disease is characterized clinicopathologi-
cally by marked serum IgG4 elevation, infi ltration of affected organs with plasmocytes bearing 
IgG4, and fi brosclerosis.
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sues and organs, sometimes impairing their func-
tion.29 Periostin is observed in the salivary glands ob-
tained from patients with chronic sialadenitis; its ex-
pression is limited to the interlobular area. In con-
trast, periostin expression is more strongly and dif-
fusely observed, not only in the interlobular capsule
but also around the damaged acinar cells and de-
stroyed ductal cells, in affected salivary glands from
patients with IgG4-related disease compared with
those of chronic sialadenitis. We have demonstrated
that periostin and TGF-beta play important roles in
the pathogenesis of IgG4-related disease.30 It is gen-
erally accepted that periostin production is induced
by IL-4 and IL-13.1,2 However, contrary to our expec-
tation, IL-13 and IL-4 has not been detected in af-
fected salivary glands from patients with IgG4-related
disease.30 Periostin could increase the synthesis
and secretion of collagen and promote epithelial-
mesenchymal transition in the lung tissues in a TGF-
beta-dependent manners.31,32 Periostin can also regu-
late the induction and proliferation of tissue fibro-
blasts.33 Collectively, there are at least two different
pathways to induce periostin in IL-13IL-4 dependent
or TGF-beta dependent manner. Our results clearly
demonstrate that periostin may contribute to fibro-
sclerosis in IgG4-related disease in a TGF-beta de-
pendent manner.30
CONCLUSIONS
We have focused primarily on periostin and its multi-
ple roles in otolaryngological diseases. Periostin
might be involved in different ways in various oto-
laryngological diseases, including AR, CRSwNP, AIA,
organized hematoma, EOM, and IgG4-related disease
(Table 1). Periostin is transiently upregulated after
mechanical stress and injury under physiological con-
ditions.34 This process is vital for normal wound heal-
ing. In contrast, continuous and longstanding overex-
pression of periostin could lead to persistent, slowly
progressive inflammation with remodeling and re-
structuring.34 There is thus a process of transition
from local, normal expression of periostin to expres-
sion under pathological conditions. Proper treatment,
including systemic or local steroids, might decrease
periostin expression. Our current understanding
about periostin has expanded from its biological roles
in bone metabolism and embryogenesis to its newly
recognized functions in allergic inflammatory reac-
tions and remodeling and the clinical implications for
wound healing, tissue repair, dental diseases, and
cancer.35-37 Periostin is expressed in the developing
teeth at sites of epithelial-mesenchymal interaction.36
This finding suggests that periostin is involved in
tooth development and maintenance of the integrity
of adult teeth. One recent report has demonstrated
that epithelial cells respond to periostin by enhancing
cellular migration and proliferation and by activating
the mTOR signaling pathway.35 Periostin overexpres-
sion is also observed in human malignant tumors
such as head and neck, lung, colon, gastric, pancre-
atic, and breast.36 Epithelial-mesenchymal transition
is an important step in tumor invasion. Periostin in-
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Fig.　9　Representative case of IgG4-related disease in an elderly Japanese woman. (A) Bilateral enlargement of submandibu-
lar glands and symmetrical enlargement of lacrimal glands were observed. (B) Axial computed tomography scan shows sym-
metrical enlargement of submandibular glands. (C) Axial-T1 weighted MRI shows enlargement of pancreas. (D) Submandibular 
gland tissue (HE, ×200) with atrophic glands, adjacent fi brosclerosis, and lymphoplasmacytic infi ltration. (E) Immunohistochemi-
cal study of submandibular gland tissue, showing positive IgG4 staining of plasma cells surrounding the atrophic glands. (F) 
Periostin immunostaining of surgical specimen obtained from a patient with chronic sialadenitis as a control. Expression of peri-
ostin is limited to the interlobular lesion (×100). (G) Periostin immunostaining in IgG4-related disease. Periostin is more strongly
and intensively infi ltrating around the acinar and ductal cells in areas of fi brosclerosing infl ammation than was the case in chron-
ic sialadenitis (×100). (H) TGF-beta immunostaining in IgG4-related disease. TGF-beta is more strongly and intensively infi ltrat-
ing around the acinar cells and ductal cells in areas of fi brosclerosing infl ammation of the affected salivary gland (×200).
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Table　1　Roles of periostin in otolaryngological diseases
Disease Role of periostin References
Allergic 
rhinitis
Th-2 driven infl ammation, 
remodeling
15
Chronic 
rhinosinusitis
Increased airway fi brosis 14, 15  
Mucous hyperproduction
Aspirin-
induced 
asthma
Increased airway fi brosis 1, 2, 14, 15, 17 
Mucus hyperproduction
Organized 
hematoma
Fibrosis, angiogenesis 20, 21 
Tissue repair 34 
Eosinophilic 
otitis media
Th-2 driven infl ammation, 
remodeling
25, 26 
IgG4-related 
disease
Fibrosclerosis 28, 30 
duces MMP-9, MMP-10, and MMP-13 production, re-
sulting in degradation of the extracellular matrix.36
This observation suggests that periostin is involved in
local tumor spread and metastasis. Furthermore, pe-
riostin produced by cancer-associated fibroblasts cre-
ates a growth-supportive microenvironment for can-
cer.37 Recent findings also suggest that periostin en-
hances angiogenesis by upregulating vascular endo-
thelial growth factor through a focal adhesion kinase-
mediated signaling pathway.36 These data indicate
that periostin is a critical matricellular component in
remodeling the tissue microenvironment in tumor
growth and metastasis.
Emerging evidence about periostin allows us to
speculate that understanding the mechanisms in-
volved in these diseases is crucial for the develop-
ment of novel therapeutic strategies to prevent or re-
verse them. To identify periostin’s precise functional
properties, which would greatly enhance our under-
standing of its pathogenetic roles, a detailed pheno-
typic and functional analysis of this protein is war-
ranted.
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